Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Acta Biochim Pol ; 70(4): 991-995, 2023 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-38011253

RESUMO

Previously, the direct interactions of Bß26-42 fibrin residues with prothrombin were demonstrated. It was also shown that forming prothrombin complexes with E- or DDE-fragments causes non-enzymatic prothrombin activation. The direct measuring of the prothrombin level in the blood plasma of patients with acute myocardial infarction (AMI) allowed us to find a situation where such an activation can occur in vivo. Blood coagulation parameters in the blood plasma of patients with AMI were measured at 2 hours, three days, and seven days after the thrombolysis by streptokinase accompanied with intravenous administration of anticoagulants: unfractionated high molecular weight heparin (HMWH) and low-molecular-weight heparin (LMWH). The prothrombin level in the blood plasma of patients with AMI was normal before thrombolytic therapy and substantially decreased after streptokinase administration. This effect was prominent in the case of concomitant anticoagulant therapy with LMWH and was not observed when HMWH was applied. It can be explained by the fact that LMWH preferentially inhibits factor Xa, while the HMWH is an effective inhibitor of both factor Xa and thrombin. This observation suggested that the prothrombin level decrease was caused by the thrombin-like activity and possible autolysis of prothrombin by thrombin. Also, thrombolytic therapy with streptokinase caused the accumulation of fibrin degradation products (FDPs), some of which were able to bind prothrombin. The dramatic decrease of prothrombin level in the blood plasma of patients with AMI during thrombolysis allowed us to conclude the non-enzymatic prothrombin activation with the following autolysis of prothrombin that contributes to the pathology.


Assuntos
Infarto do Miocárdio , Protrombina , Humanos , Protrombina/metabolismo , Protrombina/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Trombina , Fator Xa/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Heparina/farmacologia , Heparina/uso terapêutico , Estreptoquinase/uso terapêutico , Estreptoquinase/farmacologia , Terapia Trombolítica , Anticoagulantes/uso terapêutico
2.
J Burn Care Res ; 43(4): 965-970, 2022 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-34875688

RESUMO

This work is dedicated to the detection of imbalance between the pro- and anticoagulant branches of hemostasis at severe burn injuries by evaluating the content or activity of individual clotting factors. To select the targets for accurate diagnostics we measured the concentrations of soluble fibrin monomeric complexes and fibrinogen, levels of total prothrombin, factor X, protein C, and antithrombin III, and recorded the time of clotting in activated partial thromboplastin time and prothrombin time (PT) tests. Factor X level was increased in 26% of patients on the 1st day after the burn and it rose further in 62% patients on the 14th day of recovery. Increasing factor X level is assumed to be a risk factor of thrombotic complications. We propose to use it as a marker of predisposition to thrombosis at severe burn injury.


Assuntos
Queimaduras , Fator X , Anticoagulantes , Testes de Coagulação Sanguínea , Queimaduras/complicações , Humanos , Tempo de Tromboplastina Parcial , Plasma
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...